Atlas Trials

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

Clinical trial NCT05662904 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05662904
Sponsor
German Cancer Research Center
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Start date
2028-01-01
Primary completion
2029-01-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.